Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Jul;36(7):1519–1524. doi: 10.1128/aac.36.7.1519

Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.

E Singlas 1, A M Taburet 1, F Borsa Lebas 1, O Parent de Curzon 1, A Sobel 1, P Chauveau 1, B Viron 1, R al Khayat 1, J L Poignet 1, F Mignon 1, et al.
PMCID: PMC191614  PMID: 1510449

Abstract

The pharmacokinetics of didanosine were investigated following oral administration of a single 375-mg dose to eight human immunodeficiency virus-seropositive patients with normal renal function and eight human immunodeficiency virus-seropositive uremic patients. In uremic patients, the plasma half-life was longer than that in control patients (respectively, 4.5 +/- 2.2 and 1.6 +/- 0.4 h). The ratio of total plasma clearance to absolute bioavailability was four- to fivefold lower in uremic patients than in patients with normal renal function (respectively, 491 +/- 181 and 2,277 +/- 738 ml/min). Because of the decrease in elimination, concentrations in plasma were higher for uremic patients than for control patients; the maximum concentrations of drug in plasma were, respectively, 3,978 +/- 1,607 and 1,948 +/- 994 ng/ml; the areas under the concentration-time curve were, respectively, 14,050 +/- 4,262 and 3,000 +/- 956 ng.h/ml. Didanosine was removed by hemodialysis with an extraction ratio of 53% +/- 8%, a hemodialysis clearance value of 107 +/- 21 ml/min, and a fractional drug removal during a 4-h dialysis of 20% +/- 8% of the dose. Dosage adjustments are necessary in uremic patients.

Full text

PDF
1519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  2. Cooney D. A., Ahluwalia G., Mitsuya H., Fridland A., Johnson M., Hao Z., Dalal M., Balzarini J., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 1987 Jun 1;36(11):1765–1768. doi: 10.1016/0006-2952(87)90235-8. [DOI] [PubMed] [Google Scholar]
  3. Cunningham E. E., Zielezny M. A., Venuto R. C. Heroin-associated nephropathy. A nationwide problem. JAMA. 1983 Dec 2;250(21):2935–2936. [PubMed] [Google Scholar]
  4. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet. 1976;1(2):126–134. doi: 10.2165/00003088-197601020-00004. [DOI] [PubMed] [Google Scholar]
  5. Gardenswartz M. H., Lerner C. W., Seligson G. R., Zabetakis P. M., Rotterdam H., Tapper M. L., Michelis M. F., Bruno M. S. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol. 1984 Apr;21(4):197–204. [PubMed] [Google Scholar]
  6. Gwilt P. R., Perrier D. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther. 1978 Aug;24(2):154–161. doi: 10.1002/cpt1978242154. [DOI] [PubMed] [Google Scholar]
  7. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  8. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Wyvill K. M., Flora K. P., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther. 1991 Sep;50(3):278–285. doi: 10.1038/clpt.1991.137. [DOI] [PubMed] [Google Scholar]
  9. Johnson M. A., Ahluwalia G., Connelly M. C., Cooney D. A., Broder S., Johns D. G., Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem. 1988 Oct 25;263(30):15354–15357. [PubMed] [Google Scholar]
  10. Knupp C. A., Shyu W. C., Dolin R., Valentine F. T., McLaren C., Martin R. R., Pittman K. A., Barbhaiya R. H. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther. 1991 May;49(5):523–535. doi: 10.1038/clpt.1991.63. [DOI] [PubMed] [Google Scholar]
  11. Knupp C. A., Stancato F. A., Papp E. A., Barbhaiya R. H. Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1990 Nov 30;533:282–290. doi: 10.1016/s0378-4347(00)82215-x. [DOI] [PubMed] [Google Scholar]
  12. Lee C. S., Marbury T. C. Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1984 Jan-Feb;9(1):42–66. doi: 10.2165/00003088-198409010-00003. [DOI] [PubMed] [Google Scholar]
  13. Lee C. S. The assessment of fractional drug removal by extracorporeal dialysis. Biopharm Drug Dispos. 1982 Apr-Jun;3(2):165–173. doi: 10.1002/bdd.2510030207. [DOI] [PubMed] [Google Scholar]
  14. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pardo V., Aldana M., Colton R. M., Fischl M. A., Jaffe D., Moskowitz L., Hensley G. T., Bourgoignie J. J. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med. 1984 Oct;101(4):429–434. doi: 10.7326/0003-4819-101-4-429. [DOI] [PubMed] [Google Scholar]
  16. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978 Dec;6(6):547–558. doi: 10.1007/BF01062109. [DOI] [PubMed] [Google Scholar]
  17. Yarchoan R., Mitsuya H., Thomas R. V., Pluda J. M., Hartman N. R., Perno C. F., Marczyk K. S., Allain J. P., Johns D. G., Broder S. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science. 1989 Jul 28;245(4916):412–415. doi: 10.1126/science.2502840. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES